clinical trial · NCT05561309
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·unknown·n = 89
Total Knee ArthroplastyHR18034;Ropivacaine Hydrochloride Injection
brief summary
Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management compared with ropivacaine.
started
Oct 20, 2022
primary completion
Dec 1, 2024
completion
Dec 1, 2024
last updated
Mar 4, 2024
official title
A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol